Lenalidomid (Revlimid) in the Treatment of Multiple Myeloma – First Experience in the Czech Republic
Authors:
E. Novotová; R. Neuwirtová; A. Jonášová; J. Straub; I. Špička
Authors‘ workplace:
I. interní klinika 1. LF UK a VFN, Praha
Published in:
Čas. Lék. čes. 2008; 147: 623-626
Category:
Case Report
Overview
The prognosis of multiple myeloma (MM) has substantially improved during last decades due to new, so-called targeted drugs – proteasome inhibitor bortezomib and immunomodulatory drugs (ImiDs), thalidomide and lenalidomide. They could be used in various combinations and/or sequentially thanks to different mechanism of action and toxicity. Both bortezomib and thalidomide are widely used in Czech republic, however, lenalidomide was approved for the treatment of MM (and MDS) at the very latest and its usage is limited due to high costs, as well. According to the results of clinical trials lenalidomide is effective in myeloma refractory to various therapy including other new drugs.
First time in the Czech republic the combination of lenalidomide and dexamethasone was given in our center to 2 patients with relapsed myeloma as 7th and 10th line of therapy. Acceptable results of treatment with improved clinical status in the first patient enabled to suspend his therapeutic plasmaferesis. Disease stabilization lasting three months was observed also in the second patient.
Key words:
multiple myeloma, lenalidomide.
Sources
1. Anderson, K. C.: Lenalidomide and thalidomide: mechanisms of action – similarities and differences. Semin. Hematol., 2005, 42 (Suppl. 4), s. 3–8.
2. Reddy, N., Hernandez-Ilizaliturri, F. J., Deeb, G. et al.: Immunomodulatory drugs stimulate natural killer-cell function alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br. J. Haematol., 2008, 140s. 36–45.
3. Thomas, S. K., Richards, T. A., Weber, D. M.: Lenalidomide in multiple myeloma.Best Pract. Res. Clin. Haematol., 2007, 20, s. 717–735.
4. Palumbo, A., Miguel, J. S., Sonneveld, P. et al.: Lenalidomide: a new therapy for multiple myeloma. Cancer Treat. Rev., 2008, 34, s. 283–291.
5. Weber, D. M., Chen, C., Niesvizky, R. et al.: Lenalidomid plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): results of a North American Phase III study (MM-009). J. Clin. Oncol., 2006, 24, s. 427.
6. Dimopoulos, M., Spencer, A., Attal, M. et al.: Study of lenalidomide plis dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma (MM): results of a Phase III study (MM-1010). Blood, 2005, 106, 6a.
7. Richardson, P. G., Blut, E., Mitsiades, C. S. et al.: A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refrectory multiple myeloma. Blood, 2006, 108, s. 3458–3464.
8. Batts, E. D., Sanchorawala, V., Hegerfeldt, Y., Lazarus, H. M.: Azotemia associated with use of lenalidomide in plasma cell dyscrasias. Leuk. Lymphoma, 2008, 29, s. 1–8.
9. Chanan-Khan, A. A., Weber, D., Dimopoulos, M. et al.: Lenalidomide (L) in combination with dexamethasone (D) improves time to progression (TTP) in non-stem cell transplant patients (pts) with relapsed or refractory (rel/ref) multiple myeloma (MM): Analysis from MM-009 and MM-010 randomized phase III clinical trials. Blood, 2006a, 108, Abstract 3554.
10. Rajkumar, S. V., Hayman, S. R., Lacy, M. Q. et al.: Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood, 2005, 106, s. 4050–4053.
Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain managementArticle was published in
Journal of Czech Physicians
Most read in this issue
- Differential Diagnosis of the Refractory Gastroesophageal Reflux Diseases
- Hostility as the Risk Factor for Many Health Problems and Its Management
- Lenalidomid (Revlimid) in the Treatment of Multiple Myeloma – First Experience in the Czech Republic
- Pendred Syndrome Among Patients with Hypothyroidism: Genetic Diagnosis, Phenotypic Variability and Occurrence of Phenocopies